Immunologic Deficiency Syndromes Clinical Trial
Official title:
ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID
This is a phase I/II protocol to evaluate the safety and efficacy of ADA gene transfer into hematopoietic stem/progenitor cells for the treatment of adenosine deaminase (ADA)-deficiency. This condition is an autosomal recessive form of Severe Combined Immunodeficiency (SCID) characterized by impaired immune responses, recurrent infections, failure to thrive and systemic toxicity due to accumulation of purine metabolites. Transplants from an human leukocyte-antigen (HLA)-identical sibling donor is the treatment of choice, but available for a minority of patients. The use of alternative bone marrow donors or enzyme replacement therapy is associated with important drawbacks. The drug product studied in this protocol consists of autologous cluster of differentiation (CD)34+ hematopoietic stem/progenitor cells engineered ex vivo with a retroviral vector encoding the therapeutic gene ADA. The engineered CD34+ cells are infused following a nonmyeloablative conditioning with busulfan to make space in the bone marrow. The study objectives are: a) to evaluate the safety and the clinical efficacy of gene therapy, in the absence of enzyme replacement therapy; b) to evaluate the biological activity (engraftment, ADA expression) of ADA transduced CD34+ cells and their hematopoietic progeny. c) to evaluate the immunological reconstitution and purine metabolism after gene therapy.
The safety of the study will be evaluated by description of all adverse events and adverse drug reactions. The study is aimed at reaching the minimum sample size of ten patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04798677 -
Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine
|
N/A | |
| Completed |
NCT02783482 -
Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
|
Phase 3 | |
| Completed |
NCT00468273 -
A Clinical Study of Intravenous Immunoglobulin
|
Phase 3 | |
| Completed |
NCT01727895 -
Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans
|
N/A | |
| Enrolling by invitation |
NCT03478670 -
Strimvelis Registry Study to Follow-up Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)
|
||
| Terminated |
NCT00006054 -
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
|
N/A | |
| Recruiting |
NCT03920735 -
Retrospective Non-interventional Analysis of Opportunistic Infections in Immunocompromised and Frail Patients
|
||
| Completed |
NCT00001438 -
A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes
|
Phase 2 | |
| Terminated |
NCT00811174 -
Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases
|
Phase 3 | |
| Completed |
NCT00006131 -
Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster
|
N/A | |
| Recruiting |
NCT02735824 -
Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies
|
||
| Completed |
NCT02554630 -
Novel Mechanisms and Approaches to Treat Neonatal Sepsis
|
||
| Recruiting |
NCT03835312 -
Sequential Transplantation of UCBSCs and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency T1DM
|
N/A | |
| Completed |
NCT00176865 -
Stem Cell Transplant for Immunologic or Histiocytic Disorders
|
Phase 2 | |
| Completed |
NCT00001646 -
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
|
Phase 3 | |
| Completed |
NCT02630082 -
Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru
|
N/A | |
| Completed |
NCT00001158 -
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
|
N/A |